Vetra Bio
Vetra Bio is a Cambridge, UK-based biotech that uses AI/ML at the intersection of computational modelling, molecular epigenetics, and translational science to decode ageing trajectories in companion animals, with a sales-led, subscription-based go-to-market targeting pet owners, veterinary networks, diagnostics companies, and translational biology organisations.
- Company typePrivate
- Founded2026
- HeadquartersTrumpington, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingSoftware
Vetra Bio firmographics
Firmographics- Name
- Vetra Bio
- Legal name
- Vetra Bio Ltd
- Website
- https://vetrabio.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Short description
- Vetra Bio is a Cambridge, UK-based biotech that uses AI/ML at the intersection of computational modelling, molecular epigenetics, and translational science to decode ageing trajectories in companion animals, with a sales-led, subscription-based go-to-market targeting pet owners, veterinary networks, diagnostics companies, and translational biology organisations.
- Ownership category
- akta.pro rank
Vetra Bio industry classification
Industry- Product category
- Animal Health Biotechnology
- NAICS
- Veterinary Services (54194)
- akta.pro primary industry
- Clinical Research, Trials & Translational Services (Veterinary Regenerative) (HLAMANAL)
- akta.pro secondary industry
- Practice Analytics & Business Intelligence (Dashboards, Benchmarking, Forecasting) (HLAMAGAI)
Keywords
Where Vetra Bio is headquartered
LocationHeadquarters
- HQ city
- Trumpington
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Vetra Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pre-revenue / Early Stage: Vetra Bio appears to be in an early pre-commercialization stage. The company is focused on research and development using AI/ML to understand companion animal ageing. Revenue generation mechanisms have not yet been disclosed publicly.
Go-to-market motion1 record
Marketing channels1 record
Vetra Bio product offering
Product offeringCore offering
Vetra Bio develops an AI/ML platform that decodes evolutionarily conserved ageing trajectories in companion animals, using computational modelling, molecular epigenetics, and translational science to understand how biological ageing can be shifted toward longer, healthier lives. The offering is a research-oriented platform aimed at enabling longevity and healthspan interventions for pets through data-driven biological analysis.
Differentiator
Problem solved
Functional benefit
Companies that use Vetra Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Vetra Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature1 record
Vetra Bio competitors and assessment
Company assessmentEmerging players
- Cell Longevity / Span Biotech: Early-stage longevity biotech exploring companion animal healthspan applications of geroprotective interventions. Comparable as a peer in the niche of translational ageing science applied to pets.
- Embark Veterinary: Canine genetic testing and health-risk prediction company that uses genomic data and ML to predict disease and trait outcomes. Comparable as an AI/data-driven companion animal health platform with overlapping ML and predictive analytics capabilities.
- PetPace: Smart collar and health-monitoring platform collecting continuous biometric data on dogs and cats. Comparable as a data-driven companion animal health player, though focused on wearable sensing rather than AI/ML ageing trajectory modelling.
- Animal Biosciences: Veterinary biotech developing therapeutics to extend healthy lifespan in dogs. Comparable as an emerging player in the companion animal longevity space, with overlapping focus on healthspan extension in pets.
Direct peers
- Loyal for Dogs: Clinical-stage veterinary pharmaceutical company developing drugs to extend dog healthspan and lifespan. Directly comparable to Vetra Bio as both apply longevity science to companion animals, though Loyal focuses on pharmaceutical interventions rather than AI/ML trajectory analysis.
- Rejuvenate Bio: Biotech company developing gene therapies to reverse ageing in dogs, co-founded with Harvard's George Church. Comparable to Vetra Bio as a translational biotech targeting companion animal healthspan, though focused on gene therapy rather than AI-driven trajectory modelling.
Others
- Dog Aging Project (research consortium): Large NIH/University of Washington longitudinal study of ageing in companion dogs, generating one of the largest open companion animal health datasets. Comparable as an ecosystem participant generating translational ageing data that Vetra Bio could partner with or compete against.
Broad incumbents
- Antech Diagnostics (Mars Science & Diagnostics): Leading veterinary diagnostics platform offering reference lab and in-clinic testing. Comparable as a strategic buyer/channel partner for ageing-biomarker insights that Vetra Bio aims to produce for companion animal healthspan.
- Calico Life Sciences: Alphabet-backed longevity biotech pursuing ageing biology across species. Comparable as a broad incumbent in computational and molecular ageing science, though Vetra Bio is pet-specific and much earlier stage.
- Mars Petcare Biobank: Initiative by Mars Petcare generating large-scale genomic and health data on companion animals to advance pet longevity. Comparable as a well-capitalized player building longitudinal companion animal datasets for translational ageing research.
Market position
Customer concentration
Vetra Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vetra Bio leadership team
Management profileNumber of profiles
Vetra Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vetra Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vetra Bio
What does Vetra Bio do?
Vetra Bio develops an AI/ML platform that decodes evolutionarily conserved ageing trajectories in companion animals, using computational modelling, molecular epigenetics, and translational science to understand how biological ageing can be shifted toward longer, healthier lives. The offering is a research-oriented platform aimed at enabling longevity and healthspan interventions for pets through data-driven biological analysis.
Is Vetra Bio a public or private company?
Vetra Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Vetra Bio founded?
Vetra Bio was founded in 2026.
Where is Vetra Bio based?
Vetra Bio is headquartered in Trumpington, United Kingdom, in the Europe region.
How does Vetra Bio make money?
One revenue line is on record: pre-revenue / Early Stage.
Who are Vetra Bio's main competitors?
Emerging players on record are Cell Longevity / Span Biotech, Embark Veterinary, PetPace and Animal Biosciences. Direct peers are Loyal for Dogs and Rejuvenate Bio. Dog Aging Project (research consortium) is listed as an others. Broad incumbents are Antech Diagnostics (Mars Science & Diagnostics), Calico Life Sciences and Mars Petcare Biobank.
Does Vetra Bio have an API?
No public API is recorded for Vetra Bio.
What industry is Vetra Bio in?
Vetra Bio's product category is Animal Health Biotechnology. Its primary akta.pro industry code is HLAMANAL, Clinical Research, Trials & Translational Services (Veterinary Regenerative), with a secondary code of HLAMAGAI, Practice Analytics & Business Intelligence (Dashboards, Benchmarking, Forecasting). Its NAICS code is 54194.